Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia (CLL) cells from apoptosis: Role for LPA as a survival factor in CLL.

被引：0
|
作者：
Gibson, SB [1 ]
Hu, XJ [1 ]
Haney, N [1 ]
Kabore, AF [1 ]
Johnston, JB [1 ]
机构：
[1] Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB, Canada
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.4788.4788
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4788
引用
收藏
页码：280B / 280B
页数：1
相关论文
共 50 条
  • [31] Primary chronic lymphocytic leukemia (CLL) cells survival support from NLC and SDF-1a (CXCL-12) in vitro and the effect of lenalidomide (LEN)
    James, D. F.
    Choi, M. Y.
    Betty, M.
    Mosadeghi, R.
    Kipps, T. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] From normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity
    Ghia, Paolo
    Scielzo, Cristina
    Frenquelli, Michela
    Muzio, Marta
    Caligaris-Cappio, Federico
    AUTOIMMUNITY REVIEWS, 2007, 7 (02) : 127 - 131
  • [33] VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance
    Lee, YK
    Shanafelt, TD
    Bone, ND
    Strege, AK
    Jelinek, DF
    Kay, NE
    LEUKEMIA, 2005, 19 (04) : 513 - 523
  • [34] Apoptosis of B-Chronic Lymphocytic Leukemia (CLL) cells in presence of glucocorticoids and modulation of their effect by interleukin-4
    Tanghe, A
    Delforge, A
    Bernier, M
    Massy, M
    Bron, D
    Stryckmans, P
    DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA II, 1997, 3 : 141 - 145
  • [35] VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance
    Y K Lee
    T D Shanafelt
    N D Bone
    A K Strege
    D F Jelinek
    N E Kay
    Leukemia, 2005, 19 : 513 - 523
  • [36] Microenvironmental, but not chronic lymphocytic leukemia (CLL) cell-derived vascular endothelial growth factor (VEGF) is essentially involved in the apoptotic resistance of CLL-cells
    Gehrke, I
    Peasler, J.
    Poll-Wolbeck, S. J.
    Hallek, M.
    Kreuzer, K. -A
    ONKOLOGIE, 2010, 33 : 40 - 40
  • [37] Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect® CLL Registry
    Ahn, Inhye E.
    Farber, Charles Michael
    Davids, Matthew
    Grinblatt, David L.
    Lamanna, Nicole
    Mato, Anthony R.
    Nabhan, Chadi
    Kiselev, Pavel
    Swern, Arlene S.
    Flick, E. Dawn
    Bhushan, Shriya
    Sullivan, Kristen
    Sharman, Jeff
    Flowers, Christopher R.
    BLOOD, 2016, 128 (22)
  • [38] Hematologist/Oncologist Disease-Specific Expertise and Survival: Lessons from Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    Shanafelt, Tait D.
    Kay, Neil E.
    Rabe, Kari G.
    Inwards, David J.
    Zent, Clive S.
    Leis, Jose F.
    Schwager, Susan M.
    Thompson, Carrie A.
    Bowen, Deborah A.
    Witzig, Thomas E.
    Slager, Susan L.
    Call, Timothy G.
    CANCER, 2012, 118 (07) : 1827 - 1837
  • [39] Possible role of lymphoid enhancer binding factor-1 (LEF-1) for cell survival and disease progression in chronic lymphocytic leukemia (CLL)
    Poll-Wolbeck, S. J.
    Erdfelder, F.
    Gehrke, I
    Hallek, M.
    Kreuzer, K-A
    ONKOLOGIE, 2010, 33 : 240 - 240
  • [40] Interleukin-10 (IL-10) is a survival factor for B cell chronic lymphocytic leukemia (B-CLL)
    Jurlander, J
    Lau, CF
    Tan, J
    Chou, CC
    Geisler, CH
    Narula, SK
    Baumann, H
    Caligiuri, MA
    BLOOD, 1995, 86 (10) : 1371 - 1371
12345